Mid-sized biotechs pressured to accept MFN deals crafted for big pharma

A new round of most-favored nation drug pricing deals that will be announced as soon as Monday will shed light on the intense pressure the Trump administration has applied to mid-sized biopharmas and the trade-offs they must consider. About 10 companies have accepted deals, while others have resisted the pressure.

The White House has essentially offered get-out-of-jail cards exempting companies from mandatory Medicare MFN drug-pricing models, as well as relief from tariffs, in exchange for accepting deep cuts to Medicaid reimbursement...